Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ketek Risk Cannot Be Distinguished From Class, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.

You may also be interested in...



Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing

Agency says it has “learned” from controversy surrounding the antibiotic, but FDA will likely still face congressional grilling about its actions.

Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing

Agency says it has “learned” from controversy surrounding the antibiotic, but FDA will likely still face congressional grilling about its actions.

Ketek Medication Guide Suggested By FDA Staff

Two-day, two-panel advisory committee meeting will consider the risks and benefits of the antibiotic, which Sanofi-Aventis says addresses an unmet medical need.

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel